{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:40:10Z","timestamp":1792708810208,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T00:00:00Z","timestamp":1545177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00415-018-9122-2","type":"journal-article","created":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T08:05:58Z","timestamp":1545206758000},"page":"1280-1286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":208,"title":["Neurological update: MOG antibody\u00a0disease"],"prefix":"10.1007","volume":"266","author":[{"given":"Ray","family":"Wynford-Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7368-6280","authenticated-orcid":false,"given":"Valentina","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,19]]},"reference":[{"issue":"12","key":"9122_CR1","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.4049\/jimmunol.139.12.4016","volume":"139","author":"H Schluesener","year":"1987","unstructured":"Schluesener H et al (1987) A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 139(12):4016\u20134021","journal-title":"J Immunol"},{"issue":"2","key":"9122_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s001090050092","volume":"75","author":"C Bernard","year":"1997","unstructured":"Bernard C et al (1997) Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J Mol Med 75(2):77\u201388","journal-title":"J Mol Med"},{"issue":"1","key":"9122_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1471-4159.1999.0720001.x","volume":"72","author":"T Johns","year":"1999","unstructured":"Johns T, Bernard C (1999) The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem 72(1):1\u20139","journal-title":"J Neurochem"},{"issue":"1","key":"9122_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0165-5728(87)90031-2","volume":"17","author":"C Linington","year":"1987","unstructured":"Linington C, Lassmann H (1987) Antibody responses in chronic relapsing experimental allergic encephalomyelitis: correlation of serum demyelinating activity with antibody titre to the myelin\/oligodendrocyte glycoprotein (MOG). J Neuroimmunol 17(1):61\u201369","journal-title":"J Neuroimmunol"},{"issue":"3","key":"9122_CR5","first-page":"443","volume":"130","author":"C Linington","year":"1988","unstructured":"Linington C et al (1988) Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin\/oligodendrocyte glycoprotein. Am J Pathol 130(3):443\u2013454","journal-title":"Am J Pathol"},{"issue":"3","key":"9122_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1001\/archneur.56.3.311","volume":"56","author":"A Karni","year":"1999","unstructured":"Karni A et al (1999) Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch Neurol 56(3):311\u2013315","journal-title":"Arch Neurol"},{"issue":"9","key":"9122_CR7","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1177\/1352458507077622","volume":"13","author":"V Tomassini","year":"2007","unstructured":"Tomassini V et al (2007) Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Mult Scler 13(9):1086\u20131094","journal-title":"Mult Scler"},{"key":"9122_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1056\/NEJMoa022328","volume":"349","author":"T Berger","year":"2003","unstructured":"Berger T et al (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349:139\u2013145","journal-title":"N Engl J Med"},{"key":"9122_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1136\/jnnp.2005.077784","volume":"77","author":"S Rauer","year":"2006","unstructured":"Rauer S et al (2006) Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry 77:739\u2013742","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"9122_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/1352458506072189","volume":"13","author":"S Pittock","year":"2007","unstructured":"Pittock S et al (2007) Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations. Mult Scler 13(1):7\u201316","journal-title":"Mult Scler"},{"issue":"4","key":"9122_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1056\/NEJMoa063602","volume":"356","author":"J Kuhle","year":"2007","unstructured":"Kuhle J et al (2007) Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 356(4):371\u2013378","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"9122_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jneuroim.2014.03.001","volume":"270","author":"M Tanaka","year":"2014","unstructured":"Tanaka M, Tanaka K (2014) Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system. J Neuroimmunol 270(1\u20132):98\u201399","journal-title":"J Neuroimmunol"},{"issue":"3","key":"9122_CR13","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","volume":"2","author":"P Waters","year":"2015","unstructured":"Waters P et al (2015) MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2(3):e89","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"9122_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"D Wingerchuk","year":"2015","unstructured":"Wingerchuk D et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177\u2013189","journal-title":"Neurology"},{"issue":"2","key":"9122_CR15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"A Thompson","year":"2018","unstructured":"Thompson A et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173","journal-title":"Lancet Neurol"},{"key":"9122_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S et al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflamm 15:134","journal-title":"J Neuroinflamm"},{"issue":"3","key":"9122_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1212\/WNL.0000000000004117","volume":"89","author":"Y Hacohen","year":"2017","unstructured":"Hacohen Y et al (2017) Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. Neurology 89(3):269\u2013278","journal-title":"Neurology"},{"issue":"12","key":"9122_CR18","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1007\/s00415-017-8635-4","volume":"264","author":"S Mariotto","year":"2017","unstructured":"Mariotto S et al (2017) Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. J Neurol 264(12):2420\u20132430","journal-title":"J Neurol"},{"issue":"2","key":"9122_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10384-018-0561-1","volume":"62","author":"T Kezuka","year":"2018","unstructured":"Kezuka T, Ishikawa H (2018) Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis. Jpn J Ophthalmol 62(2):101\u2013108","journal-title":"Jpn J Ophthalmol"},{"key":"9122_CR20","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","volume":"89","author":"E Hennes","year":"2017","unstructured":"Hennes E et al (2017) Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 89:900\u2013908","journal-title":"Neurology"},{"issue":"5","key":"9122_CR21","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/ene.13602","volume":"25","author":"Y Wong","year":"2018","unstructured":"Wong Y et al (2018) Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome. Eur J Neurol 25(5):782\u2013786","journal-title":"Eur J Neurol"},{"issue":"3","key":"9122_CR22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/acn3.164","volume":"2","author":"M Spadaro","year":"2015","unstructured":"Spadaro M et al (2015) Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol 2(3):295\u2013301","journal-title":"Ann Clin Transl Neurol"},{"key":"9122_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.msard.2017.09.023","volume":"18","author":"L Zhou","year":"2017","unstructured":"Zhou L et al (2017) Cerebral cortical encephalitis followed by recurrent CNS demyelination in a patient with concomitant anti-MOG and anti-NMDA receptor antibodies. Mult Scler Relat Disord 18:90\u201392","journal-title":"Mult Scler Relat Disord"},{"key":"9122_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2018.03.019","author":"J Zhou","year":"2018","unstructured":"Zhou J et al (2018) An unusual case of anti-MOG CNS demyelination with concomitant mild anti-NMDAR encephalitis. J Neuroimmunol. https:\/\/doi.org\/10.1016\/j.jneuroim.2018.03.019 . (Epub ahead of print)","journal-title":"J Neuroimmunol"},{"key":"9122_CR25","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.msard.2017.07.023","volume":"17","author":"M Nakamura","year":"2017","unstructured":"Nakamura M et al (2017) A case of MOG antibody-positive bilateral optic neuritis and meningoganglionitis following a genital herpes simplex virus infection. Mult Scler Relat Disord 17:148\u2013150","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"9122_CR26","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1177\/0883073817724927","volume":"32","author":"J Vieira","year":"2017","unstructured":"Vieira J, Sequeira J, Brito M (2017) Postinfectious anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis and myelitis. J Child Neurol 32(12):996\u2013999","journal-title":"J Child Neurol"},{"issue":"1","key":"9122_CR27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12883-017-0858-6","volume":"17","author":"Y Nakamura","year":"2017","unstructured":"Nakamura Y et al (2017) Anti-MOG antibody-positive ADEM following infectious mononucleosis due to a primary EBV infection: a case report. BMC Neurol 17(1):76","journal-title":"BMC Neurol"},{"key":"9122_CR28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-017-0984-5","volume":"14","author":"P Peschl","year":"2017","unstructured":"Peschl P et al (2017) Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. J Neuroinflamm 14:208","journal-title":"J Neuroinflamm"},{"key":"9122_CR29","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005560","author":"A Cobo-Calvo","year":"2018","unstructured":"Cobo-Calvo A et al (2018) Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000005560 . (Epub ahead of print)","journal-title":"Neurology"},{"issue":"9","key":"9122_CR30","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00415-017-8583-z","volume":"264","author":"A Cobo-Calvo","year":"2017","unstructured":"Cobo-Calvo A et al (2017) MOG antibody-related disorders: common features and uncommon presentations. J Neurol 264(9):1945\u20131955","journal-title":"J Neurol"},{"key":"9122_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","volume":"89","author":"S Ramanathan","year":"2018","unstructured":"Ramanathan S et al (2018) Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 89:127\u2013137","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"9122_CR32","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M et al (2017) Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 140(12):3128\u20133138","journal-title":"Brain"},{"key":"9122_CR33","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm 13:280","journal-title":"J Neuroinflamm"},{"issue":"4","key":"9122_CR34","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/1352458515593406","volume":"22","author":"S Ramanathan","year":"2015","unstructured":"Ramanathan S et al (2015) Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler J 22(4):470\u2013482","journal-title":"Mult Scler J"},{"issue":"10","key":"9122_CR35","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1007\/s00415-017-8615-8","volume":"264","author":"D Biotti","year":"2017","unstructured":"Biotti D et al (2017) Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France. J Neurol 264(10):2173\u20132175","journal-title":"J Neurol"},{"issue":"1","key":"9122_CR36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","volume":"75","author":"S Hamid","year":"2018","unstructured":"Hamid S et al (2018) Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease. JAMA Neurol 75(1):65\u201371","journal-title":"JAMA Neurol"},{"issue":"4","key":"9122_CR37","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","volume":"75","author":"Y Hacohen","year":"2018","unstructured":"Hacohen Y et al (2018) Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody\u2013associated disease. JAMA Neurol 75(4):478\u2013487","journal-title":"JAMA Neurol"},{"issue":"2","key":"9122_CR38","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1212\/NXI.0000000000000322","volume":"4","author":"R Ogawa","year":"2017","unstructured":"Ogawa R et al (2017) MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm 4(2):e322","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"9122_CR39","doi-asserted-by":"publisher","first-page":"e0170847","DOI":"10.1371\/journal.pone.0170847","volume":"12","author":"H Stiebel-Kalish","year":"2017","unstructured":"Stiebel-Kalish H et al (2017) Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study. PLoS One 12(1):e0170847","journal-title":"PLoS One"},{"key":"9122_CR40","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","volume":"13","author":"F Pache","year":"2016","unstructured":"Pache F et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflamm 13:282","journal-title":"J Neuroinflamm"},{"key":"9122_CR41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/jnnp-2014-308984","volume":"86","author":"M Jurynczyk","year":"2015","unstructured":"Jurynczyk M et al (2015) Overlapping CNS inflammatory diseases: differentiating features of NMO and MS. J Neurol Neurosurg Psychiatry 86:20\u201325","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"9122_CR42","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1177\/1352458514528762","volume":"20","author":"T Kalincik","year":"2014","unstructured":"Kalincik T et al (2014) Risk of relapse phenotype recurrence in multiple sclerosis. Mult Scler 20(11):1511\u20131522","journal-title":"Mult Scler"},{"issue":"14","key":"9122_CR43","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1212\/WNL.0b013e3182887957","volume":"80","author":"L Matthews","year":"2013","unstructured":"Matthews L et al (2013) Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 80(14):1330\u20131337","journal-title":"Neurology"},{"issue":"9","key":"9122_CR44","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1586\/ern.09.83","volume":"9","author":"V Tomassini","year":"2009","unstructured":"Tomassini V, Palace J (2009) Multiple sclerosis lesions: insights from imaging techniques. Expert Rev Neurother 9(9):1341\u20131359","journal-title":"Expert Rev Neurother"},{"issue":"9","key":"9122_CR45","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"D Wingerchuk","year":"2007","unstructured":"Wingerchuk D et al (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6(9):805\u2013815","journal-title":"Lancet Neurol"},{"issue":"3","key":"9122_CR46","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/brain\/aww350","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M et al (2017) Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain 140(3):617\u2013627","journal-title":"Brain"},{"issue":"5","key":"9122_CR47","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1212\/NXI.0000000000000257","volume":"3","author":"M Spadaro","year":"2016","unstructured":"Spadaro M et al (2016) Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 3(5):e257","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"9122_CR48","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1177\/1352458515622986","volume":"22","author":"S Jarius","year":"2016","unstructured":"Jarius S et al (2016) Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in \u2018pattern II multiple sclerosis\u2019 and brain biopsy findings in a MOG-IgG-positive case. Mult Scler J 22(12):1541\u20131549","journal-title":"Mult Scler J"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-018-9122-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-9122-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-9122-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T08:27:09Z","timestamp":1694507229000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-018-9122-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,19]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["9122"],"URL":"https:\/\/doi.org\/10.1007\/s00415-018-9122-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,19]]},"assertion":[{"value":"17 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. R. Wynford-Thomas\u2019 clinical research fellow Grant is co-funded by Novartis. Dr. A. Jacob has received research Grants from Biogen Idec, Alexion Pharmaceuticals and speaker fees from Biogen, Chugai, Sanofi-Genzyme and Terumo-BC. Dr. V. Tomassini has received research support and honoraria from Biogen Idec, and honoraria and travel Grants from Biogen Idec and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}